Benchmark: FDA Proposed Reclassification of Oncology Nucleic Acid-Based Test Systems

Take this benchmark to assess how much you would benefit from taking the course on FDAs proposed reclassification of oncology therapeutic nucleic acid-based test systems (from class III to class II with special controls). In a few minutes, youll see where your understanding is strong and where the course can close gaps.

This quick check is not an examit probes how well you grasp the implications of the proposal: why it matters, who it affects, and what could change in practice.

• Clarify the intent: Why FDA believes special controls can assure safety and effectiveness for these tests.
• Spot the impact: How a shift to 510(k) may change timelines, evidence expectations, and market dynamics.
• Plan operationally: What manufacturers, labs, and clinicians might need to do differently (predicates, validation, labeling alignment).
• Manage risk: How special controls target false results, device performance, and interpretation.
• Engage effectively: Where public comments can shape the final rule.

Use your results to decide if the full course will help you participate in the rulemaking process, prepare submissions, adjust workflows, or guide clinical adoption with confidence.